Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma.

Abstract

Like humans, canine lymphomas are treated by chemotherapy cocktails and frequently develop multiple drug resistance (MDR). Their shortened clinical timelines and tumor accessibility make canines excellent models to study MDR mechanisms. Insulin-sensitizers have been shown to reduce the incidence of cancer in humans prescribed them, and we previously demonstrated that they also reverse and delay MDR development in vitro. Here, we treated canines with MDR lymphoma with metformin to assess clinical and tumoral responses, including changes in MDR biomarkers, and used mRNA microarrays to determine differential gene expression. Metformin reduced MDR protein markers in all canines in the study. Microarrays performed on mRNAs gathered through longitudinal tumor sampling identified a 290 gene set that was enriched in Anaphase Promoting Complex (APC) substrates and additional mRNAs associated with slowed mitotic progression in MDR samples compared to skin controls. mRNAs from a canine that went into remission showed that APC substrate mRNAs were decreased, indicating that the APC was activated during remission. In vitro validation using canine lymphoma cells selected for resistance to chemotherapeutic drugs confirmed that APC activation restored MDR chemosensitivity, and that APC activity was reduced in MDR cells. This supports the idea that rapidly pushing MDR cells that harbor high loads of chromosome instability through mitosis, by activating the APC, contributes to improved survival and disease-free duration.

• Authors: Terra G Arnason, Valerie MacDonald-Dickinson, Matthew Casey Gaunt, Gerald F Davies, Liubov Lobanova, Brett Trost, Zoe E Gillespie, Matthew Waldner, Paige Baldwin, Devon Borrowman, Hailey Marwood, Frederick S Vizeacoumar, Franco J Vizeacoumar, Christopher H Eskiw, Anthony Kusalik, Troy A A Harkness
• Journal: Cancers (Cancers (Basel)) Vol. 14 Issue 17 (Aug 30 2022) ISSN: 2072-6694 [Print] Switzerland
• PMID: 36077749 (Publication Type: Journal Article)